Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. [PDF]
PLoS ONE, 2014 The Notch ligand Delta-like 4 (Dll4) is highly expressed in vascular endothelium and has been shown to play a pivotal role in regulating tumor angiogenesis.
Kiersten Marie Miles +12 more
doaj +1 more source
Immunotherapy for Gastrointestinal Malignancies [PDF]
, 2014 Gastrointestinal (GI) malignancies (esophageal, gastric, pancreatic, intra- and extra-biliary ductal, hepatocellular, and colorectal cancers) are an important cause of cancer incidence and mortality in the US and globally.
Davar, Diwakar, Sun, Weijing
core +1 more source
Pricing in the Market for Anticancer Drugs [PDF]
, 2015 In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months.
Bach, Peter B. +3 more
core +1 more source
Personalizing medicine for metastatic colorectal cancer: Current developments [PDF]
, 2014 Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence and mortality. In 2012, colorectal cancer was the second most prevalence cancer among males (9%) and the third among females (8%).
De Mello, Ramon Andrade +2 more
core +1 more source
European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer [PDF]
, 2017 On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/ folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer ...
Caleno, Mariapaola +8 more
core +1 more source
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists [PDF]
, 2014 Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors ...
Christophe Tournigand +2 more
core +1 more source
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI [PDF]
, 2014 The VELOUR study demonstrated a survival benefit for FOLFIRI + aflibercept versus FOLFIRI + placebo in metastatic colorectal cancer (mCRC) patients who progressed on oxaliplatin-based chemotherapy.
Bridgewater, J +3 more
core +2 more sources
Complications of Ziv-Aflibercept in Choroidal and Retinal Vascular Diseases
Open Journal of Ophthalmology, 2023 Hussain Ahmad Khaqan +7 more
openalex +3 more sources
Do anti-VEGFs used in the ophthalmic clinic cause Müller glial cell stress? [PDF]
, 2023 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Biosciences Graduate Program Institute of Biosciences Instituto de Biociências Letras e Ciências Exatas Universidade Estadual ...
Caio Vinicius Saito +5 more
core +2 more sources
Cancer Medicine, Volume 9, Issue 4, Page 1485-1494, February 2020., 2020 Mismatch repair proficient colorectal cancer has been refractory to single‐agent programmed cell death protein 1 inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in ...
Mark Yarchoan +19 more
wiley +1 more source